Clinical Trial Update: Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Sintilimab with intraperitoneal and intravenous Paclitaxel plus oral S-1 in gastric cancer with peritoneal metastasis; efficacy and saf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Peritoneal Metastases

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• S-1 (tegafur/gimeracil/oteracil)
• Sintilimab (sintilimab)

Snippet

Sponsor: Ruijin Hospital | Conditions: Gastric Cancer Stage IV, Peritoneal Metastases | Phase 2 | Status: UNKNOWN